UNIQURE N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.53 USD | -0.22% |
|
-3.00% | -33.09% |
| Apr. 12 | Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director | CI |
| Apr. 02 | UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating | MT |
Chart calendar uniQure N.V.
bb.QQu12FHYUcm4ysRs8FmkW9YvBi9ppWWC0KKGRkkOZF4.NFTy7DyJZaLr5_AWpmCUabNtYRsbxlLAh-ncNARPIQwgWY3hN70Lg4qEsw~c9a015aab392eccd942bf002db46bc91
Upcoming events on uniQure N.V.
Past events on uniQure N.V.
| 2024-03-17 | UBS CNS Day |
| 2024-03-12 03:40 pm | Leerink Partners Global Biopharma Conference |
| 2024-03-05 02:10 pm | TD Cowen Health Care Conference |
| 2024-02-26 07:05 am | Q4 2023 Earnings Release |
| 2024-02-08 03:00 pm | Guggenheim Healthcare Talks Biotechnology Conference |
| 2023-12-19 08:30 am | Business Update Call |
| 2023-11-15 08:00 am | Extraordinary Shareholders Meeting |
| 2023-11-13 | Stifel Healthcare Conference |
| 2023-11-07 07:05 am | Q3 2023 Earnings Release |
| 2023-10-27 02:30 am | European Society of Gene and Cell Therapy Conference - CNS & sensory diseases II, Session 10a |
| 2023-09-28 09:45 am | Cantor Global Healthcare Conference |
| 2023-09-06 | Citi BioPharma Conference |
| 2023-09-06 02:15 pm | Wells Fargo Healthcare Conference |
| 2023-08-08 | Goldman Sachs Boston Bus Tour Conference |
| 2023-08-01 07:05 am | Q2 2023 Earnings Release |
| 2023-06-21 08:30 am | AMT-130 Phase I/II Clinical Trial Results Call |
| 2023-06-13 03:00 am | Annual General Meeting |
| 2023-05-19 03:00 pm | American Society of Gene and Cell Therapy Meeting - Abstract No #1503 |
| 2023-05-18 06:45 pm | American Society of Gene Cell Therapy Meeting - Abstract No #165 |
| 2023-05-18 04:45 pm | American Society of Gene Cell Therapy Meeting - Abstract No #110 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 6,53 5,61 16.45% | 31,0 102 -69.53% | 465 416 11.71% | 101 22,0 358.74% | 14,6 13,7 6.73% | 55,6 |
|
EBITDA Million EUR | Released Forecast Spread | -103 -104 1.05% | -95,2 -115 17.39% | 282 248 13.66% | -128 -192 33.63% | -250 -251 0.7% | -165 |
|
EBIT Million EUR | Released Forecast Spread | -109 -109 0.44% | -104 -23,7 -336.54% | 276 240 14.81% | -136 -204 33.33% | -261 -264 1.24% | -185 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -111 -105 -5.78% | -117 -9,82 -1094.17% | 295 257 14.81% | -122 -170 28.69% | -282 -275 -2.72% | -205 |
|
Net income Million EUR | Released Forecast Spread | -111 -105 -6.12% | -104 -13,3 -682.38% | 293 253 15.71% | -120 -166 27.44% | -284 -276 -3.16% | -202 |
|
EPS EUR | Released Forecast Spread | -2,79 -2,60 -7.37% | -2,32 -0,73 -216.94% | 6,25 5,41 15.59% | -2,57 -3,50 26.58% | -5,96 -5,78 -3.09% | -4,02 |
| Announcement Date | 02/03/20 | 01/03/21 | 25/02/22 | 27/02/23 | 28/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 51,2 10,6 383.53% | 1,70 12,4 -86.3% | 0,49 9,05 -94.59% | 1,47 3,20 -54.18% | 97,4 19,6 396.56% | 4,83 28,5 -83.04% | 2,20 157 -98.6% | 1,32 4,40 -70.06% | 6,16 5,67 8.73% | 5,82 | 7,73 | 21,6 | 26,1 | 14,3 |
|
EBITDA Million EUR | Released Forecast Spread | 3,48 -25,3 113.75% | -49,5 -22,8 -117.26% | -52,9 -35,0 -51.04% | -58,2 -21,0 -176.68% | 27,3 -20,2 235.03% | -65,4 32,6 -300.69% | -57,0 -39,5 -44.28% | -74,2 -55,5 -33.56% | -53,0 -50,6 -4.78% | -50,9 | -50,2 | -50,7 | -52,2 | |
|
EBIT Million EUR | Released Forecast Spread | 1,84 -30,6 106.01% | -51,3 -45,7 -12.24% | -55,2 -44,2 -24.84% | -60,3 -56,4 -6.99% | 25,1 -42,7 158.85% | -67,3 -31,6 -113.35% | -59,0 28,0 -311.22% | -76,2 -40,0 -90.46% | -56,9 -59,2 3.96% | -52,0 | -51,8 | -34,7 | -44,8 | -35,6 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | 6,98 -26,5 126.34% | -44,9 -45,1 0.57% | -38,8 -40,4 4.03% | -48,8 -52,8 7.56% | 6,26 -41,0 115.27% | -71,2 -17,7 -303.22% | -62,0 90,6 -168.38% | -83,5 -25,9 -221.95% | -64,7 -60,5 -6.86% | -54,7 | -51,0 | -49,1 | -36,9 | -36,9 |
|
Net income Million EUR | Released Forecast Spread | 7,29 -27,8 126.16% | -44,3 -36,7 -20.64% | -38,5 -41,7 7.82% | -48,5 -53,5 9.38% | 6,45 -36,8 117.54% | -70,1 -29,9 -134.43% | -62,1 94,7 -165.59% | -83,4 -29,2 -185.26% | -67,5 -61,1 -10.39% | -55,7 | -52,7 | -51,5 | -29,8 | -36,9 |
|
EPS EUR | Released Forecast Spread | 0,15 -0,70 121.49% | -0,95 -0,73 -29.55% | -0,83 -0,93 10.95% | -1,03 -1,13 8.69% | 0,14 -0,80 117.74% | -1,48 -0,82 -79.72% | -1,31 2,30 -156.88% | -1,75 -0,73 -138.93% | -1,41 -1,30 -8.23% | -1,17 | -1,12 | -1,10 | -0,77 | -0,96 |
| Announcement Date | 25/02/22 | 02/05/22 | 08/08/22 | 02/11/22 | 27/02/23 | 09/05/23 | 01/08/23 | 07/11/23 | 28/02/24 | - | - | - | - | - |
More events
Past sector events for uniQure N.V.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- QURE Stock
- Calendar uniQure N.V.
